Cite
HARVARD Citation
De Placido, S. et al. (2018). Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet oncology. 19 (4), pp. 474-485. [Online].